Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
XBiotech, Inc. Identifier:
First received: August 31, 2011
Last updated: October 29, 2012
Last verified: October 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):